Supernus Pharmaceuticals (SUPN) Short term Debt (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 9 years of Short term Debt data on file, last reported at $31.1 million in Q4 2025.

• Short term Debt for Q4 2025 came in at $31.1 million, down 34.41% year-over-year; the trailing twelve-month figure through Dec 2025 was $31.1 million (down 34.41% YoY), and the FY2025 annual result was $31.1 million, down 34.41% from the prior year.
• Short term Debt climbed to $31.1 million in Q4 2025 per SUPN's latest filing, from $11.2 million in the prior quarter.
• Over five years, Short term Debt peaked at $400.9 million in Q2 2022 and troughed at $11.2 million in Q3 2025.
• A 5-year average of $56.9 million and a median of $45.4 million in 2021 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2022 and 2023: Short term Debt surged 1603.1% in 2022, then plunged 94.83% in 2023.
• A 5-year view of Short term Debt shows it stood at $44.8 million in 2021, then plunged by 52.9% to $21.1 million in 2022, then soared by 146.54% to $52.1 million in 2023, then retreated by 9.08% to $47.3 million in 2024, then tumbled by 34.41% to $31.1 million in 2025.
• Business Quant data shows SUPN's Short term Debt at $31.1 million in Q4 2025, $11.2 million in Q3 2025, and $30.0 million in Q1 2025.